On January 2, 2018 Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, reported that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, and Gregory K. Chow, Senior Vice President and Chief Financial Officer, will participate at the upcoming Biotech Showcase 2019 Conference on Monday, January 7, 2019 at 11:00 a.m. PST in San Francisco, CA (Press release, Aptose Biosciences, JAN 2, 2019, View Source [SID1234532356]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Presentation Details:

Date: Monday, January 7, 2019
Time: 11:00 a.m. PST
Location: Track Yosemite – C (Ballroom Level)
Hilton San Francisco Union Square, 333 O’Farrell Street, San Francisco, CA 94102
Webcast: View Source;tp_key=d5803514a3

The audio webcast will be archived shortly after the live event and will be available through the Aptose website at View Source

The Company will also be hosting institutional investor and partnering meetings at the LifeSci Advisors Corporate Access Event taking place in San Francisco, on January 8 and 9, 2019.

To schedule a meeting with Aptose, investors can register on the online system managed by the Company’s US investor relations firm LifeSci Advisors, LLC, or make a request via e-mail at [email protected].

On January 2, 2019 Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, reported that Marc N. Casper, president and chief executive officer, will present at the 37th Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2019, at 4:00 p.m. (PST) at the Westin St. Francis, San Francisco, Calif (Press release, Thermo Fisher Scientific, JAN 2, 2019, View Source [SID1234532355]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

You can access the live webcast of the presentation in the Investors section of our website, www.thermofisher.com.

On January 2, 2019 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) reported that it will present at the 37th Annual J.P. Morgan Healthcare Conference at 2:30 p.m. PT (5:30 p.m. ET) on Monday, Jan. 7, 2019, in San Francisco. Kevin Gorman, Chief Executive Officer, will present at the conference (Press release, Neurocrine Biosciences, JAN 2, 2019, View Source;p=RssLanding&cat=news&id=2381876 [SID1234532354]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live presentation will be webcast and may be accessed on the Company’s website under Investors at www.neurocrine.com. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month

On January 2, 2019 Merus N.V. (Nasdaq: MRUS) ("Merus", "we", "our" or the "Company"), a clinical-stage immuno-oncology company developing Biclonics, innovative full-length human bispecific antibody therapeutics, reported that it has agreed to grant Betta Pharmaceuticals Co Ltd (SHE: 300558) an exclusive license to develop and commercialize Merus Biclonics MCLA-129 in China (Press release, Merus, JAN 2, 2019, View Source;p=RssLanding&cat=news&id=2381816 [SID1234532353]). Merus will retain all rights outside of China.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, Betta Pharmaceuticals has agreed to be responsible for clinical development and commercialization of MCLA-129 in China. As a key strategic component of the collaboration, Betta will retain a contract manufacturing organization with experience in filing Initial New Drug (IND) applications with U.S. and European regulatory authorities in order to produce clinical trial materials for the Chinese market and rest of world. Betta will facilitate regulatory filings and early stage clinical trial materials supply for potential use by Merus for development of MCLA-129 outside of China.

"This latest collaboration is representative of our long term strategy to unlock Biclonics platform value beyond our core programs," said Ton Logtenberg, Ph.D., Chief Executive Officer of Merus. "Betta Pharma is a market leader in EGFR inhibitors in China and we anticipate will be a strong partner for Merus in MCLA-129 development."

MCLA-129 is a Biclonics binding to EGFR and cMET for the treatment of solid tumors. EGFR is an important oncogenic driver in many cancers; the upregulation of c-MET signaling has been associated with resistance to EGFR inhibition.

MCLA-129 has two distinct mechanisms of action. First, Merus’ Dock & Block mechanism of action blocks the signaling of EGFR as well as c-MET, with the potential to inhibit tumor growth and survival. Second, MCLA-129 utilizes GlymaxX antibody-dependent cell-mediated cytotoxicity (ADCC)-enhancement technology designed for greater cell-killing potential. Because the Dock & Block and ADCC mechanism of action is based on the co-expression of EGFR and c-MET, it is expected to have less toxicity compared to agents targeting EGFR alone.

In preclinical studies, MCLA-129 showed a significant reduction in tumor volume for EGFR inhibitor resistant lung cancer models lacking immune cells. Additionally, in cell lines that co-express both EGFR and c-MET, MCLA-129 effectively induced tumor cell lysis at low antibody concentrations.

In addition to receiving an upfront payment, Merus will be eligible to receive payments contingent upon Betta Pharmaceuticals achieving certain specified development and commercial goals in China. Merus will also be eligible to receive tiered royalty payments on sales in China from Betta Pharmaceuticals. Betta Pharmaceuticals will be eligible to receive payments contingent upon Merus achieving certain specified development and commercial goals, and will be eligible to receive tiered royalty payments on sales outside of China from Merus.

On January 2, 2019 Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) reported that it will present at the 37th Annual J.P. Morgan Healthcare Conference at 4:00 PM PT (7:00 PM ET) on Tuesday, January 8, 2018. Live audio of the presentation can be accessed by visiting the "Events" page of the company’s website at investor.pacira.com (Press release, Pacira Pharmaceuticals, JAN 2, 2019, View Source;p=irol-newsArticle&ID=2381850 [SID1234532345]). A replay of the webcast will also be available for two weeks following the event.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!